{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:58:16Z","timestamp":1788919096439,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40120-024-00616-7","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:02:12Z","timestamp":1714104132000},"page":"917-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dental Adverse Effects of Anti-CD20 Therapies"],"prefix":"10.1007","volume":"13","author":[{"given":"H\u00e9l\u00e8ne","family":"Bartak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Fareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouha","family":"Ben Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Viard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-530X","authenticated-orcid":false,"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lebrun-Frenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"issue":"8","key":"616_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022;21(8):693\u2013703.","journal-title":"Lancet Neurol"},{"issue":"7","key":"616_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"issue":"2","key":"616_CR3","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","volume":"18","author":"C Ruetsch-Chelli","year":"2021","unstructured":"Ruetsch-Chelli C, Bresch S, Seitz-Polski B, Rosenthal A, Desnuelle C, Cohen M, et al. Memory B cells predict relapse in rituximab-treated myasthenia gravis. Neurotherapeutics. 2021;18(2):938\u201348.","journal-title":"Neurotherapeutics"},{"issue":"15","key":"616_CR4","doi-asserted-by":"publisher","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","volume":"94","author":"J Poupart","year":"2020","unstructured":"Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020;94(15):e1645\u201356.","journal-title":"Neurology"},{"key":"616_CR5","unstructured":"EMA. European Medicines Agency. 2018. Ocrevus. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ocrevus. Cited 19 Nov 2023."},{"issue":"6","key":"616_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"key":"616_CR7","unstructured":"EMA. European Medicines Agency. 2021. Kesimpta. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kesimpta. Cited 19 Nov 2023."},{"key":"616_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102988","volume":"52","author":"NR Oksbjerg","year":"2021","unstructured":"Oksbjerg NR, Nielsen SD, Blinkenberg M, Magyari M, Sellebjerg F. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord. 2021;52: 102988.","journal-title":"Mult Scler Relat Disord"},{"key":"616_CR9","unstructured":"A review of the efficacy and tolerability of venlafaxine\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/19698585\/. Cited 19 Nov 2023."},{"key":"616_CR10","unstructured":"Multiple Sclerosis-A Demyelinating Disorder and Its Dental Considerations-A Literature Review with Own Case Report\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/37508941\/. Cited 19 Nov 2023."},{"issue":"4","key":"616_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","volume":"174","author":"J Ciron","year":"2018","unstructured":"Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018;174(4):255\u201364.","journal-title":"Rev Neurol (Paris)"},{"key":"616_CR12","unstructured":"EMA. European Medicines Agency. 2018. MabThera. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera. Cited 19 Nov 2023."},{"issue":"2","key":"616_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"616_CR14","unstructured":"Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/. Cited 28 Feb 2024."},{"issue":"3","key":"616_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cdoe.12445","volume":"47","author":"C Sexton","year":"2019","unstructured":"Sexton C, Lalloo R, Stormon N, Pateman K, van der Mei I, Campbell J, et al. Oral health and behaviours of people living with Multiple Sclerosis in Australia. Community Dent Oral Epidemiol. 2019;47(3):201\u20139.","journal-title":"Community Dent Oral Epidemiol"},{"issue":"2","key":"616_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.joms.2012.05.008","volume":"71","author":"SA Danesh-Sani","year":"2013","unstructured":"Danesh-Sani SA, Rahimdoost A, Soltani M, Ghiyasi M, Haghdoost N, Sabzali-Zanjankhah S. Clinical assessment of orofacial manifestations in 500 patients with multiple sclerosis. J Oral Maxillofac Surg. 2013;71(2):290\u20134.","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"616_CR17","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.3390\/ijerph17113979","volume":"17","author":"F Covello","year":"2020","unstructured":"Covello F, Ruoppolo G, Carissimo C, Zumbo G, Ferrara C, Polimeni A, et al. Multiple sclerosis: impact on oral hygiene, dysphagia, and quality of life. Int J Environ Res Public Health. 2020;17(11):3979.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"616_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/cdoe.12512","volume":"48","author":"N Manchery","year":"2020","unstructured":"Manchery N, Henry JD, Nangle MR. A systematic review of oral health in people with multiple sclerosis. Community Dent Oral Epidemiol. 2020;48(2):89\u2013100.","journal-title":"Community Dent Oral Epidemiol"},{"key":"616_CR19","unstructured":"Is there an association between multiple sclerosis and oral health?| Evidence-Based Dentistry [Internet]. https:\/\/www.nature.com\/articles\/s41432-021-0159-1. Cited 19 Nov 2023."},{"key":"616_CR20","unstructured":"Differences in the Incidence of Pathologic Lesions on the Oral Mucosa in Patients Undergoing Hemodialysis vs Renal Organ Transplant Recipients Subjected to Long-term Pharmacologic Immunosuppressive Therapy\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/32222390\/. Cited 19 Nov 2023."},{"key":"616_CR21","unstructured":"Candida-associated denture stomatitis in patients after immunosuppression therapy\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/16504690\/. Cited 19 Nov 2023."},{"issue":"5","key":"616_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.autrev.2012.12.002","volume":"12","author":"LPC Seguro","year":"2013","unstructured":"Seguro LPC, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. Autoimmun Rev. 2013;12(5):629\u201332.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"616_CR23","first-page":"666","volume":"10","author":"SS Beeraka","year":"2013","unstructured":"Beeraka SS, Natarajan K, Patil R, Manne RK, Prathi VS, Kolaparthi VSK. Clinical and radiological assessment of effects of long-term corticosteroid therapy on oral health. Dent Res J. 2013;10(5):666\u201373.","journal-title":"Dent Res J"},{"key":"616_CR24","unstructured":"Oral Health Status and Multiple Sclerosis: classic and non-classic manifestations-case report\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/36135218\/. Cited 19 Nov 2023."},{"key":"616_CR25","unstructured":"EMA. European Medicines Agency. 2018. Lemtrada. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lemtrada. Cited 19 Nov 2023."},{"key":"616_CR26","unstructured":"EMA. European Medicines Agency. 2018. Mavenclad. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad. Cited 19 Nov 2023."},{"key":"616_CR27","unstructured":"EMA. European Medicines Agency. 2018. Aubagio. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aubagio. Cited 19 Nov 2023."},{"key":"616_CR28","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit\u2014GLATIRAMER VIATRIS 20 mg\/ml, solution injectable en seringue pr\u00e9remplie - Base de donn\u00e9es publique des m\u00e9dicaments [Internet]. https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=61853027&typedoc=R. Cited 19 Nov 2023."},{"key":"616_CR29","unstructured":"EMA. European Medicines Agency. 2018. Tecfidera. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecfidera. Cited 19 Nov 2023."},{"key":"616_CR30","unstructured":"EMA. European Medicines Agency. 2018. Gilenya. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gilenya. Cited 19 Nov 2023."},{"key":"616_CR31","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit\u2014MITOXANTRONE ACCORD 2 mg\/mL, solution \u00e0 diluer pour perfusion\u2014base de donn\u00e9es publique des m\u00e9dicaments [Internet]. https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=61760943&typedoc=R. Cited 19 Nov 2023."},{"key":"616_CR32","unstructured":"EMA. European Medicines Agency. 2018. Tysabri. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tysabri. Cited 19 Nov 2023."},{"key":"616_CR33","unstructured":"EMA. European Medicines Agency. 2021. Ponvory. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ponvory. Cited 19 Nov 2023."},{"key":"616_CR34","unstructured":"Periodontitis AAE of OT in a P with MSACR of N. An adverse effect of ocrelizumab treatment in a patient with multiple sclerosis: a case report of necrotizing periodontitis. Dent Adv Res [Internet]. 2023 Apr 4; https:\/\/www.gavinpublishers.com\/article\/view\/an-adverse-effect-of-ocrelizumab-treatment-in-a--patient-with-multiple-sclerosis-a-case-report-of-necrotizing-periodontitis. Cited 19 Nov 2023."},{"issue":"109","key":"616_CR35","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.biopha.2018.11.121","volume":"1","author":"Z Payandeh","year":"2019","unstructured":"Payandeh Z, Bahrami AA, Hoseinpoor R, Mortazavi Y, Rajabibazl M, Rahimpour A, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019;1(109):2415\u201326.","journal-title":"Biomed Pharmacother"},{"issue":"14","key":"616_CR36","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"23","author":"J de S\u00e8ze","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023;23(14):1004795.","journal-title":"Front Immunol"},{"key":"616_CR37","doi-asserted-by":"crossref","unstructured":"Subcutaneous absorption of biotherapeutics: knowns and unknowns | Drug metabolism & disposition [Internet]. https:\/\/dmd.aspetjournals.org\/content\/42\/11\/1881.long. Cited 7 Mar 2024.","DOI":"10.1124\/dmd.114.059238"},{"issue":"13","key":"616_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814064","volume":"28","author":"JB Torres","year":"2022","unstructured":"Torres JB, Roodselaar J, Sealey M, Ziehn M, Bigaud M, Kneuer R, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022;28(13): 814064.","journal-title":"Front Immunol"},{"key":"616_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02437","author":"MA Migotto","year":"2019","unstructured":"Migotto MA, Mardon K, Orian J, Weckbecker G, Kneuer R, Bhalla R, et al. Efficient distribution of a novel zirconium-89 labeled anti-cd20 antibody following subcutaneous and intravenous administration in control and experimental autoimmune encephalomyelitis-variant mice. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.02437.","journal-title":"Front Immunol"},{"key":"616_CR40","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2023","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2023;271:1515\u201335.","journal-title":"J Neurol"},{"key":"616_CR41","unstructured":"Anti-CD20-mediated B cell depletion in autoimmune diseases: successes, failures and future perspectives\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/32229095\/. Cited 19 Nov 2023."},{"issue":"1","key":"616_CR42","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1038\/s41598-022-07336-8","volume":"12","author":"A Troci","year":"2022","unstructured":"Troci A, Zimmermann O, Esser D, Krampitz P, May S, Franke A, et al. B cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients. Sci Rep. 2022;12(1):3728.","journal-title":"Sci Rep"},{"issue":"8","key":"616_CR43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41577-021-00506-1","volume":"21","author":"KE Huus","year":"2021","unstructured":"Huus KE, Petersen C, Finlay BB. Diversity and dynamism of IgA-microbiota interactions. Nat Rev Immunol. 2021;21(8):514\u201325.","journal-title":"Nat Rev Immunol"},{"key":"616_CR44","unstructured":"Role of secretory IgA in infection and maintenance of homeostasis\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/23201924\/. Cited 19 Nov 2023."},{"issue":"1","key":"616_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00011-020-01418-x","volume":"70","author":"E Chang","year":"2021","unstructured":"Chang E, Kobayashi R, Fujihashi K, Komiya M, Kurita-Ochiai T. Impaired salivary SIgA antibodies elicit oral dysbiosis and subsequent induction of alveolar bone loss. Inflamm Res. 2021;70(1):151\u20138.","journal-title":"Inflamm Res"},{"key":"616_CR46","unstructured":"Intestinal Candida albicans overgrowth in IgA deficiency\u2014ScienceDirect [Internet]. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0091674923005663. Cited 19 Nov 2023."},{"key":"616_CR47","unstructured":"IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM\u2014PubMed [Internet]. https:\/\/pubmed.ncbi.nlm.nih.gov\/31537840\/. Cited 19 Nov 2023."},{"issue":"439","key":"616_CR48","doi-asserted-by":"publisher","first-page":"eaan1217","DOI":"10.1126\/scitranslmed.aan1217","volume":"10","author":"J Fadlallah","year":"2018","unstructured":"Fadlallah J, El Kafsi H, Sterlin D, Juste C, Parizot C, Dorgham K, et al. Microbial ecology perturbation in human IgA deficiency. Sci Transl Med. 2018;10(439):eaan1217.","journal-title":"Sci Transl Med."},{"key":"616_CR49","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.csbj.2021.02.010","volume":"19","author":"A Radaic","year":"2021","unstructured":"Radaic A, Kapila YL. The oralome and its dysbiosis: New insights into oral microbiome-host interactions. Comput Struct Biotechnol J. 2021;19:1335\u201360.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"616_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/prd.12317","volume":"82","author":"TE Van Dyke","year":"2020","unstructured":"Van Dyke TE, Sima C. Understanding resolution of inflammation in periodontal diseases: is chronic inflammatory periodontitis a failure to resolve? Periodontol 2000. 2020;82(1):205\u201313.","journal-title":"Periodontol 2000"},{"key":"616_CR51","unstructured":"Assessment of Entamoeba gingivalis and Trichomonas tenax in patients with chronic diseases and its correlation with some risk factors\u2014PMC [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9288630\/. Cited 19 Nov 2023."},{"issue":"1","key":"616_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.34172\/japid.2021.007","volume":"13","author":"I Robo","year":"2021","unstructured":"Robo I, Heta S, Lasku G, Ostreni V. Gingival recession and attachment loss: cross-sectional and retrospective data of 10 years. J Adv Periodontol Implant Dent. 2021;13(1):22\u20137.","journal-title":"J Adv Periodontol Implant Dent"},{"issue":"3","key":"616_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1590\/2177-6709.21.3.018-029.oin","volume":"21","author":"AS Jati","year":"2016","unstructured":"Jati AS, Furquim LZ, Consolaro A. Gingival recession: its causes and types, and the importance of orthodontic treatment. Dent Press J Orthod. 2016;21(3):18\u201329.","journal-title":"Dent Press J Orthod"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00616-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00616-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00616-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T03:34:31Z","timestamp":1716953671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00616-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00616-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest but Christine Lebrun-Frenay is an Editorial Board member of Neurology and Therapy. Christine Lebrun-Frenay was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No personal information or identifiable patient details are included in the manuscript. Therefore, there is no need for patient consent as the content does not disclose any confidential or sensitive information. Additionally, we would like to confirm that our case series did not involve any human subjects directly. Consequently, Institutional Review Board (IRB) approval was not sought for this particular study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}